Ongoing Multi-Center, Multi-Cohort Phase 1 Trial for the treatment of solid tumors expressing the tumor-associated antigen 5T4

[Maxone73]

ALG.APV-527 is aimed (for the purpose of the trial) at adult patients with advanced/metastatic solid tumors likely to express 5T4

aptevotherapeutics.com/pipe...

[KocoPr]

Excellent for patients who have the 5T4 marker. I have never seen this test in regular practice so i can imagine each prospect will require a tumor biopsy. Correct?

Broad Utility: 5T4 is a well-defined tumor antigen expressed on many different types of malignancies including, non-small cell lung, renal, pancreas, prostate, breast, colorectal, gastric, ovarian and cervical cancers. Conversely, 5T4 has limited expression on normal tissues, making it an attractive target for cancer immunotherapy.

Reduced Toxicity: ALG.APV-527 employs a novel mechanism of action to direct the therapeutic 4-1BB immune response towards the tumor, thereby potentially reducing the harmful side effects of systemic immune stimulation while providing a strong tumor-directed immune activation. ALG.APV-527 contains an Fc that does not interact with Fc gamma receptors, it has the potential to be less toxic than 1st generation monospecific 4-1BB antibodies.